Moomoo AI 已提取核心信息
On March 5, 2024, Panbela Therapeutics, Inc. received a notification from The Nasdaq Stock Market LLC indicating that the company's common stock will be delisted due to non-compliance with the minimum stockholders equity requirement of $2.5 million as stipulated in Listing Rule 5550(b)(1). The delisting process will commence with the suspension of trading on Nasdaq at the opening of the market on March 7, 2024, followed by the filing of a Form 25 Notification of Delisting with the SEC after the appeal period has passed. Panbela Therapeutics expects its common stock to be quoted on the OTC Pink Market under the same symbol 'PBLA' during the interim. The company has the option to request a review of the Panel's decision within 15 days or the Nasdaq Listing and Hearing Review Council may opt to review the decision within 45 calendar days. Panbela Therapeutics plans to continue its SEC filings and periodic reports despite the delisting.
On March 5, 2024, Panbela Therapeutics, Inc. received a notification from The Nasdaq Stock Market LLC indicating that the company's common stock will be delisted due to non-compliance with the minimum stockholders equity requirement of $2.5 million as stipulated in Listing Rule 5550(b)(1). The delisting process will commence with the suspension of trading on Nasdaq at the opening of the market on March 7, 2024, followed by the filing of a Form 25 Notification of Delisting with the SEC after the appeal period has passed. Panbela Therapeutics expects its common stock to be quoted on the OTC Pink Market under the same symbol 'PBLA' during the interim. The company has the option to request a review of the Panel's decision within 15 days or the Nasdaq Listing and Hearing Review Council may opt to review the decision within 45 calendar days. Panbela Therapeutics plans to continue its SEC filings and periodic reports despite the delisting.
2024年3月5日，Panbela Therapeutics, Inc.收到纳斯达克股票市场有限责任公司的通知，该公司的普通股将因未遵守上市规则5550 (b) (1) 规定的250万美元的最低股东权益要求而退市。退市程序将从2024年3月7日开盘时暂停纳斯达克的交易开始，然后在上诉期结束后向美国证券交易委员会提交25号表格的退市通知。Panbela Therapeutics预计，在此期间，其普通股将在场外粉红市场上市，股票代码相同 “PBLA”。该公司可以选择在15天内要求对该小组的决定进行审查，或者纳斯达克上市和听证会审查委员会可以选择在45个日历日内审查该决定。尽管已退市，Panbela Therapeutics仍计划继续向美国证券交易委员会提交文件和定期报告。
2024年3月5日，Panbela Therapeutics, Inc.收到纳斯达克股票市场有限责任公司的通知，该公司的普通股将因未遵守上市规则5550 (b) (1) 规定的250万美元的最低股东权益要求而退市。退市程序将从2024年3月7日开盘时暂停纳斯达克的交易开始，然后在上诉期结束后向美国证券交易委员会提交25号表格的退市通知。Panbela Therapeutics预计，在此期间，其普通股将在场外粉红市场上市，股票代码相同 “PBLA”。该公司可以选择在15天内要求对该小组的决定进行审查，或者纳斯达克上市和听证会审查委员会可以选择在45个日历日内审查该决定。尽管已退市，Panbela Therapeutics仍计划继续向美国证券交易委员会提交文件和定期报告。
有用
没用